SCHAUMBURG, Ill., May 24, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced its planned launch of piperacillin and tazobactam for injection, the generic form of Zosyn®, in three distinct single dose vial forms. Piperacillin and tazobactam is used for the treatment of patients with moderate to severe bacterial infections. According to IMS data, the U.S. market for injectable piperacillin and tazobactam approximated $749 million.
